Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Vinorelbine in HER2- Advanced Breast Cancer
NCT05296577Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2022
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anlotinib in breast cancer (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-Free Survival at 24 months. Started Mar 2022; status: recruiting.
02
Drugs
anlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05296577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296577.